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Background/aim: Hepatitis B virus (HBV) vaccination rates are insufficient in high-risk patients worldwide. This study aimed to
investigate the screening, immunization, and vaccination rates in three high-risk groups for HBV infection: allogeneic hematopoietic
stem cell transplantation (AHSCT), renal transplantation (RT), and chronic hepatitis C (CHC) groups.
Materials and methods: The serological data of consecutive patients between 2014 and 2019 were reviewed using the hospital database.
Results: The HBV screening rates were 100.0%, 90.4%, and 82.4% in the AHSCT, CHC, and RT groups, respectively (p = 0.003). The
immunization rates against HBV through either previous exposure or vaccination were 79.5%, 71.7%, and 46.5% in the AHSCT, RT,
and CHC groups, respectively (p < 0.001). The HBV vaccination rate was significantly low in the CHC group (71.5%, 69.0%, 34.6%
in the AHSCT, RT, and CHC groups, respectively, p < 0.001). If patients lost their immunity due to immunosuppressive therapy were
accounted, the vaccination rates increased to 95.2% in the AHSCT group and 72.9% in the RT group. The rate of annual screening for
HBV status was 97.9% in the AHSCT group, but it was only 23.9% in the RT group.
Conclusion: HBV screening and vaccination rates were significantly lower in the RT and CHC groups than in the AHSCT group.
Key words: Vaccination, Hepatitis B virus, immunity

1. Introduction
Hepatitis B virus (HBV) infections result in acute or
chronic hepatitis. Acute HBV infection can lead to
liver failure, and chronic HBV infection can progress to
cirrhosis, liver failure, liver cancer, and death. Thus, HBV
infection has a significant burden on the healthcare system
due to its high morbidity and mortality rates and treatment
costs. Considering that almost half of adult patients are
asymptomatic and unaware of their HBV infections, HBV
transmission and persistence within the population are still
a major public health problem with a significant burden
[1]. According to the World Health Organization (WHO)
report, 240 million people test positive for hepatitis B
surface antigen (HBsAg); thus, they are diagnosed with
chronic HBV infection1. The prevalence of HBV infection
significantly varies worldwide. Turkey, a country with
1

intermediate endemicity, has an HBV infection prevalence
between 2% and 8% [2–5].
Vaccination is the most effective method of preventing
vertical and horizontal transmission of HBV infection.
Therefore, HBV vaccination is strictly recommended
in some high-risk adults who frequently receive blood
or blood products, patients on dialysis, patients with
diabetes, recipients of solid organ transplants, patients
with chronic liver disease and human immunodeficiency
virus infection, individuals working in prisons, individuals
injecting drugs, household and sexual contacts of
individuals diagnosed with chronic HBV infection, men
who have sex with men, individuals with multiple sexual
partners, healthcare workers, and others who may be
exposed to blood, blood products, or other potentially
infectious body fluids during their work.

World Health Organization. Hepatitis B Vaccines: WHO Position Paper [online]. Website http://www.who.int/wer/en/ [accessed 7 July 2017].
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Patients with a history of renal transplantation (RT),
allogeneic hematopoietic stem cell transplantation
(AHSCT), or chronic hepatitis C (CHC) must be
vaccinated against HBV without missing any single
patient. Furthermore, the ACIP recommended annual
HBV screening in AHSCT and RT recipients [6]. The
data for global vaccination rates in the high-risk groups
are insufficient, although some studies have reported
unacceptably low vaccination rates even in the highrisk groups [7,8]. These disappointingly low vaccination
rates in the high-risk groups emphasized that we should
review our practices for HBV screening and vaccination
to achieve the WHO 2030 target of eliminating HBV
worldwide. In this study, we aimed to investigate the
current HBV vaccination and immunization status of the
aforementioned high-risk patients.
2. Materials and methods
The HBV serology data of patients recruited to another
study were used after a waiver of informed consent was
obtained (Hacettepe University local ethics committee
study approval identification code: GO 18/186). Patients
aged ≥18 years with a history of RT (159 recipients),
AHSCT (47 recipients), and CHC (83 patients) recruited
from the nephrology, hematology, and gastroenterology
departments, respectively, were included in the study.
The data for HBV serology and HBV deoxyribonucleic
acid (DNA) from January 1, 2014 to June 30, 2019 were
reviewed to identify the HBV screening, vaccination,
and immunization status of these patients. Patients who
were not screened were excluded from the analysis of
immunization and vaccination rates. The vaccination
rate analysis also excluded patients with chronic HBV
infection, occult hepatitis B, and HBV immunity gained by
previous exposure. The vaccination status was obtained by
face-to-face interviews or telephone calls in patients who
were anti-HBs antibody positive but were not tested for
total anti-HBV core antigen (HBc) antibody.
2.1. Definitions
HBV screening: Patients underwent HBsAg, antiHBs, and anti-HBc total antibody testing.
Screening rates were calculated as follows:
Number of screened patients
Number of all patients in that group
HBV immunization: Patients had ≥10 mIU/mL
anti-HBs antibody titers and either tested positive or
negative for total anti-HBc antibody. In other words, HBV
immunization suggested that anti-HBs positivity was
gained through either vaccination or infection.
Immunization rates were calculated as follows:
Number of anti-HBs-positive patients
Number of all patients in that group - (chronic HBV
infection + non-screened patients)
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Hence, the following patients were excluded from the
denominator value:
· Patients who were not screened at all.
· Patients who had chronic HBV infection.
HBV vaccination: Patients had ≥10 mIU/mL antiHBs antibody titers and tested negative for total anti-HBc
antibody.
Vaccination rates were calculated as follows:
Number of patients who are anti-HBs positive and
anti-HBc total negative
Number of patients who have indication(s) for HBV
vaccination
In the denominator, the following patients were
excluded:
· Patients who were not screened at all.
· Patients who had chronic HBV infection.
· Patients who had occult hepatitis B.
· Patients who had immunity against HBV gained by
previous exposure.
Occult hepatitis B: Patients tested positive for total
anti-HBc antibody, together with negativity for HBsAg
(anti-HBs and HBV DNA can be positive or negative).
Chronic Hepatitis B infection: Patients had positive
HBsAg and anti-HBc total (HBV DNA can be positive or
negative).
Serological markers of HBV infection were determined
using commercially available immunoassays throughout
the study. All assays were performed according to the
manufacturers’ instructions. HBsAg, anti-HBs, anti-HBc
immunoglobulin M, and anti-HBc immunoglobulin
G
were
determined
using
chemiluminescent
microparticle immunoassays via the Architect system
(Abbott Laboratories, USA). HBV DNA was evaluated
quantitatively by Cobas AmpliPrep real-time polymerase
chain reaction (Roche Diagnostic Systems Inc., Germany).
HBV DNA levels expressed as copy mL–1 were converted
to IU mL–1 for standardization according to the WHO
standards as directed by the manufacturer.
2.2. Statistical analysis
Frequency and percentages were reported for categorical
variables. Fisher’s exact test was used for comparing the
three independent groups in terms of categorical variables.
Moreover, the same test was applied for post-hoc analysis
by adjusting the p-values with Bonferroni correction. A
two-sided p-value <0.05 was considered significant. All
statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS) version 23.0 (IBM
Corp., Armonk, NY, USA) for Windows.
3. Results
3.1. Screening rates
The HBV screening rates were 100.0%, 90.4%, and 82.4%
in the AHSCT, CHC, and RT groups, respectively (Figure).
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Figure. Hepatitis B virus screening, immunization, vaccination rates. The screening, immunization, and vaccination rates of AHSCT,
RT, and CHC groups are shown in this figure. AHSCT: Allogeneic hematopoietic transplant recipients, RT: Renal transplant recipients,
CHC: Chronic hepatitis C patients.

The screening rates were significantly different between
the three groups (p = 0.001), with the AHSCT group
achieving the highest screening rate among the three
groups (p = 0.002). Additionally, the annual screening rate
was 97.9% in the AHSCT group, but it was only 23.3% in
the RT group.
3.2. Immunization rates
The immunization rates were 79.5%, 71.7%, and 46.5% in
the AHSCT, RT, and CHC groups, respectively (Figure). The
immunization rates were significantly different among the
three groups (P< 0.001). The CHC group had significantly
lower HBV immunization rate than the AHSCT and
RT groups (Figure). Immunity was gained by previous
exposure in 10.2%, 18.1%, and 21.1% of RT recipients,
AHSCT recipients, and CHC patients, respectively.
3.3. Vaccination rates
The vaccination rates were far below the ideal rate of
100%. Specifically, the CHC group had significantly lower
vaccination rate than the other two groups (Figure).
Considering patients who were previously vaccinated but
lost their immunity due to immunosuppressive drugs, the
HBV vaccination rates increased to 95.2% and 72.9% in the
AHSCT and RT groups, respectively. Immunity was lost
during follow-up in 8 (18.1%) and 5 (3.9%) patients in the
AHSCT and RT groups, respectively, all of whom gained
anti-HBs positivity through vaccination. In contrast to RT
patients who lost their immunity against HBV, all patients
with AHSCT were revaccinated. This further emphasizes
the importance of annual screening for HBV in the highrisk groups.
Occult hepatitis B and chronic HBV infections were
detected in 1 (0.7%) and 4 (3.0%) patients undergoing RT,

1 (2.1%) and 3 (6.3%) patients undergoing AHSCT, and
4 (5.3%) and 4 (5.3%) patients with CHC, respectively.
Compensated cirrhosis was observed in 19 (22.8%)
patients with CHC. Significantly, only 1 of 6 (16.7%)
patients with cirrhosis indicated for HBV vaccination was
vaccinated.
4. Discussion
Although HBV vaccination is the most efficient method of
eliminating HBV infection worldwide, this study revealed
that the screening and vaccination rates were far from the
ideal rates in the high-risk groups, and annual screening
rate was significantly low among RT recipients. The high
rate of acquisition of HBV immunity gained through
previous exposure (10.2%, 18.1%, and 21.1% in the RT,
AHSCT, and CHC groups, respectively) suggested that
HBV infection is still an important health problem among
the high-risk groups in Turkey.
Although the AHSCT group was managed according
to the Centers for Disease Control and Prevention/ACIP
guidelines [9], the RT and CHC groups had significantly low
screening (82.4% and 90.4%, respectively) and vaccination
rates (69.0% and 34.6%, respectively). The vaccination
rate was 95.2% in the AHSCT group when patients who
lost their immunity due to immunosuppressive treatment
were considered. The high screening and vaccination
rates in the AHSCT group can be possibly attributed
to the protocol-based approach used in all AHSCT
recipients in the pretransplant and posttransplant periods.
Furthermore, the posttransplant annual HBV serology
screening rate was 97.9% in the AHSCT group, which is
possibly attributed to the dedicated nurses working in
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the hematology department. In the RT group, both the
screening and vaccination rates were significantly lower
than the recommended levels. Although long-term followup after transplantation is performed by a nephrologist in
RT recipients, a significantly low (23.3%) annual screening
rate of HBV serology is observed in these RT recipients.
Hence, patients who lost their immunity during follow-up
are possibly difficult to determine and thus, are not usually
revaccinated. Similar to the RT group, the vaccination
rates of CHC patients (46.5%) in the gastroenterology
department and patients with cirrhosis (16.7%) were
significantly low. These results emphasized the importance
of dedicated healthcare personnel (mostly nurses) and the
appropriate application of routine protocols to achieve
high HBV vaccination rate in the high-risk groups. The
availability of dedicated healthcare staff who continuously
assess the HBV vaccination status of patients and who
consistently remind doctors about HBV vaccination and
the preparation of checklists and obligatory orders for
HBV vaccination needs to be established in hospitals. The
education programs directed to patients and healthcare
staff might improve HBV screening and vaccination
compliance. Launay et al. [10] conducted pre-post cluster
randomized study to investigate the effects of training of
healthcare staff, free on-site vaccine availability, and the
combination of these two interventions. Interestingly,
training of healthcare staff was not associated with any
beneficial effect on neither vaccination acceptance nor
coverage. However, the group receiving the combination
of two interventions had significantly higher vaccination
acceptance than the free on-site vaccination group.
Therefore, training of healthcare staff and free on-site
vaccine availability are important issues that need to be
addressed to increase HBV vaccination coverage. Although
vaccination is free of charge in Turkey, HBV vaccination
rates were unacceptably low in the RT and CHC groups.
Therefore, in real-life clinical practice, several challenges
are encountered, which should be solved to achieve the
recommended HBV vaccination rates.
Considering the significantly high HBV exposure
risk, HBV vaccination is required in the specific highrisk groups. In a study comprising 1257 hepatitis C
virus ribonucleic acid-positive subjects in the United
States of America, the HBsAg positivity rate was 5.8%,
and 58.8% of the patients were previously exposed
to HBV [11]. The prevalence of HBV infection in RT
patients was 4.2% according to a study from Brazil, and
immunosuppression after RT led to HBV activation and
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liver-related complications [12]. Çakar et al. [13] showed
that out of the 197 AHSCT recipients, 6.1% was HBsAg
positive. Consistent with previous reports, our study
demonstrated that HBV exposure was frequently observed
in RT recipients (13.7%), AHSCT recipients (25.5%), and
CHC patients (30.6%). Occult hepatitis B and chronic
HBV infections were observed in 0.7% and 3.0% in the RT,
2.1% and 6.3% in the AHSCT, and 5.3% and 5.3% in the
CHC groups, respectively. HBV immunity was gained by
previous exposure in 10.2%, 18.1%, and 21.1% of patients
in the RT, AHSCT, and CHC groups, respectively. Patients
who gained their immunity by vaccination were at high
risk of losing their immunity due to immunosuppressive
treatment. Immunity was lost during follow-up in 18.1%
of patients with AHSCT and 3.1% of patients with
RT, emphasizing the importance of annual serological
screening in these high-risk groups.
In conclusion, previous HBV exposure was substantially
frequent in all high-risk groups. Although the screening
rates for HBV were greater than 80%, the vaccination rates
were far from the recommended rate, particularly for the
RT and CHC groups. Furthermore, the loss of immunity
gained by vaccination due to immunosuppressive
treatment necessitates annual screening and revaccination.
The lack of awareness for HBV infection in the high-risk
groups requires further studies to identify the challenges
encountered during HBV screening and vaccination to
achieve the WHO 2030 target. Furthermore, multifaceted
awareness campaigns should be organized to improve
HBV vaccination rate in high-risk groups in Turkey.
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